RxDoctor Payments Data

Rubin Patel, MD

Internal Medicine · Orangeburg, SCNPI 1336587526

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 30.3% of the total. Reporting peaked in 2019 at $353 and has fallen 68.6% since, to $111 in 2025.

$1,646in general payments, 2019–2025

Across 98 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$500
  • Novartis$413
  • E.r. Squibb & Sons, L.L.C.$295
  • AbbVie$108
  • Merck$94
  • AstraZeneca$89
  • plus $147 from 4 others
$181,370in research payments, 2019–2025

Across 25 payments — averaging $7254.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Molecular Systems, Inc.$181K

What the payments were for

  • Food & beverage$1,646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,646 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$64,988
Medicare patients
217
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$11,952
Pramipexole DihydrochloridePramipexole Di-Hcl30$150
Pantoprazole Sodium28$126
Gabapentin12$90
Oxycodone Hcl17$64
Donepezil Hcl30$62
Levofloxacin11$61
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$51
Prednisone11$44
Carvedilol13$33
Amlodipine Besylate15$25

Paid to pharmacies, not to this prescriber.

Other internal medicine in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →